7 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Tuberculosis: • Endogenous ... Active TB: • ... Tuberculosis Treatment ... : Active TB: • ... Initiating Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Tuberculosis: • Endogenous ... Active TB: • ... Tuberculosis Treatment ... : Active TB: • ... Initiating Treatment
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
and Disease in ... TB Disease: • ... drug dosing recommendations ... Guidelines for dosing ... #HIVAIDS #pharmacology
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
disease who are ... contacts of infectious ... #Tuberculosis #MDRTB ... antimicrobials #regimens #pharmacology ... #dosing #idsa #
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
Cytomegalovirus Infections ... Preventing CMV Disease ... CMV end-organ disease ... best prevented by using ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
to Table 5 for dosing ... Note: Active TB ... IDSA #Prevention #Treatment ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
Antiviral agents with activity ... recommended for KS treatment ... IDSA #Prevention #Treatment ... opportunistic #infections ... #HIVAIDS #pharmacology